Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22424946 | 1.00 | USP2 (0.43) | USP2HPGDTSHRESR1POLB | |
| SCHEMBL21146459 | 1.00 | USP2 (0.43) | USP2HPGDTSHRESR1POLB | |
| SCHEMBL30195005 | 0.80 | TSHR (0.64) | USP2HPGDTSHRMAPK1ALDH1A1 | |
| SCHEMBL22424961 | 0.79 | HPGD (0.44) | HPGDTSHRPOLBPTK2BHSD17B10 | |
| SCHEMBL21146454 | 0.79 | HPGD (0.44) | HPGDTSHRPOLBPTK2BHSD17B10 | |
| SCHEMBL22425160 | 0.79 | HPGD (0.44) | HPGDTSHRPOLBPTK2BHSD17B10 | |
| SCHEMBL21146732 | 0.76 | DRD2 (0.35) | HPGDTSHRALOX15PTK2BHSD17B10 | |
| SCHEMBL12433043 | 0.74 | USP2 (0.58) | USP2HPGDTSHRMAPK1 | |
| SCHEMBL29392938 | 0.73 | MAPT (0.54) | HPGDTSHRALOX15PTK2BHSD17B10 | |
| SCHEMBL17075123 | 0.73 | MAPT (0.54) | HPGDTSHRALOX15PTK2BHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720843-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-10-14 | — | — | EP | disclosed |
| US-20200291008-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200291008-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| WO-2019111107-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291008-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | USP2 1407/4885HPGD 82/4885TSHR 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.